...cisplatin-based adjuvant chemotherapy revealed that low MRE11A and high UBLQN4 expression were independent factors to predict shorter overall survival in multivariable analysis (p=0.02, HR=3.74, 95% C.I., 1.19-11.76; p=0.01, HR=5.11, 95% C.I., 1.45-18.03, respectively)....MRE11A and UBQLN4 may serve as predictors for treatment response to cisplatin regimens and prognosis in ESCC patients.